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CHAPTER 1: INTRODUCTION 
1.1. Methamphetamine (METH) 
1.1.1. History of METH Use 
Methamphetamine (METH) is a methylated amphetamine (Chemical structures are 
presented in Figure 1.1) with psychostimulant properties. Amphetamine was synthesized 
in Germany in 1887 by Romanian chemist Lazăr Edeleanu, while METH was synthesized 
in 1893 by Japanese scientist Nagai Nagayoshi. Akira Ogata used iodine and red 
phosphorous synthesized crystallized METH in 1919. They provided the basis for 
production of the drug on a larger scale [1]. Amphetamine and METH were first used to 
help with respiratory problems and nasal congestion respectively. Thereafter, METH 
quickly became a popular medication during the 1940s and 1950s. During World War II, 
METH was used to help the soldiers stay alert. Abuse of the drug reached its peak in the 
1960s. Following this, the Drug Abuse Control Amendments of 1965 and the 
Comprehensive Drug Abuse Prevention and Control Act of 1970 restricted the use of 
METH, and it was classified as a Schedule II drug [2]. In the 1980s, a crystalline form of 
METH that could be smoked, called “ice”, began to be imported from Asia to Hawaii 
[3]. This highly addictive form of METH quickly found its way to the U.S. West Coast and 
slowly began working its way east. By 1990, METH had replaced cocaine as the stimulant 
of choice among drug users in many areas of California [4]. With increasing numbers of 
large-scale manufacturers in Mexico and other parts of the world, METH continues to be 
a significant problem in the U.S. Today METH can only be prescribed for Attention Deficit 
Hyperactivity Disorder, extreme obesity, and narcolepsy. According to the Substance 
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Abuse and Mental Health Services Administration report, the number of patients treated 
for METH abuse increased by 50 percent in 2014 compared to 2009. The United Nations 
Office on Drugs and Crime reported that the amount of METH seized worldwide has 
increased by 158 percent during the last five years [5]. According to the World Drug Report 
2015 (United Nations Office on Drugs and Crime 2015), North America continues to be 
one of the major consumers and producers of METH worldwide. This indicates that METH 
abuse should be considered a serious public health problem in the United States. 
1.1.2. Properties of METH 
METH comes in a variety of forms, such as a pure crystalline hydrochloride salt 
and formulated tablets. Routes of administration include intravenous injection, smoking, 
oral ingestion, and intranasal sniffing [6, 7]. Smoking is the most common route of 
administration. When smoked or injected, METH produces an intensely pleasurable initial 
rush that lasts only a few minutes, followed by an extended period of euphoria [8].  
METH is a synthetic stimulant that affects the brain and central nervous system 
(CNS) [9]. It stimulates the release of dopamine (DA), serotonin (5-HT) and 
norepinephrine, and blocks their reuptake [10]. The presence of a large amount of these 
neurotransmitters in the synapses produces sensations of euphoria, feelings of invincibility, 
increased wakefulness, heightened sexual experiences, and hyperactivity that results from 
increased energy for extended periods of time. Deleterious short-term effects include rapid 
pulse, shallow breathing, hyperthermia, decreased appetite, increased respiration, 
confusion, irritability, chest pain, hypertension, convulsions, anxiety, aggressiveness, and 
symptoms of psychosis such as paranoia and hallucinations [11, 12]. This period is 
followed by mental and physical exhaustion, dizziness, reduced concentration, hunger, 
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decreased energy, and a desire for more METH [1]. Cognitive impairments and changes in 
the brain that result in symptoms similar to those of Parkinson's disease may occur [13]. 
Long-term use of METH is associated with neurotoxicity manifested as psychosis, anxiety, 
cognitive impairments, psychological dependence, and clinical depression that may lead to 
homicidal and suicidal ideation and action [8]. The medical use of METH is now confined 
to circumstances such as obesity, Attention Deficit Hyperactivity Disorder and narcolepsy 
[14]. 
 
Figure 1.1. Chemical structures of amphetamine (left) and METH (right). 
(pubchem.ncbi.nlm.nih.gov).  
1.1.3. Molecular Mechanism Underlying METH Abuse 
Deep within the brain is a set of structures called the limbic system. It contains the 
brain’s reward circuit, which controls and regulates our ability to feel pleasure [15]. Feeling 
pleasure is the primary motivation for humans to repeat drug-taking behavior. When the 
reward circuit is activated, each individual cell in the circuit produces chemical and 
electrical signals [16]. After METH administration, the drug quickly enters the brain. 
METH facilitates the release of the catecholamines DA, 5-HT, and noradrenaline from 
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nerve terminals in the brain, and inhibits their uptake. This leads to an increase in the 
synaptic concentration of these neurotransmitters and results in increased stimulation of 
postsynaptic receptors. To induce pleasurable effects, DA neurons release the 
neurotransmitter DA in the reward circuit. The released DA acts on DA receptors and 
actives a downstream signal. When a reward is encountered, the pre-synaptic cell releases 
a large amount of DA in a sudden burst. The excess of DA in the synaptic cleft is removed 
by DA transporters (DATs). Higher doses of METH can profoundly increase the release of 
DA from a neuron leading to high DA levels in the synapse where it becomes trapped since 
METH prevents the transporters from removing it [17]. The post-synaptic cell is activated 
to dangerously high levels because DA remains in the synapse, which causes powerful 
feelings of euphoria and makes METH incredibly addictive. 
1.2. METH Neurotoxicity 
METH can cause neurotoxicity. The Interagency Committee on Neurotoxicology 
defines neurotoxicity as permanent and reversible effects on the structure or function of the 
nervous system that can cause at least one of the following: loss of the neuronal 
components (e.g. synthesizing enzymes, receptors, transporters); a loss of the entire neuron 
and components therein (degeneration); histological signs of neuronal damage (silver 
staining, gliosis, swollen axons); and a persistent behavioral abnormality associated with 
the drug. This definition encompasses neuronal dysfunction in addition to degeneration, 
which is usually equalized with the term neurotoxicity. The established molecular 
mechanisms involved in mediating METH neurotoxicity include monoamine terminal 
(DAergic and 5HTergic) damage, mitochondrial dysfunction, hyperthermia, inflammation, 
excitotoxicity, and oxidative stress. 
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Hyperthermia occurs after the administration of high doses of METH [18, 19], and 
its occurrence is important for the development of METH neurotoxicity in DA and 5-HT 
terminals. For instance, in mice, multiple injections of high-dose METH at room 
temperature produced a significant depletion of DA in the striatum; however, equivalent 
doses of METH administered in a cold environment blocked striatal DA and 5-HT 
depletions [20]. Hyperthermia by itself does not decrease striatal DA levels in rodents [21]. 
Hyperthermia might interact with other known mediators of METH neurotoxicity, such as 
increased glutamate (GLU) neurotransmission and oxidative stress [22]. For example, 
inhibition of METH-induced hyperthermia decreases the formation of reactive oxygen 
species (ROS) in the striatum that, in turn, attenuates the damage to DA terminals [23]. 
1.2.1. METH Effects on Catecholaminergic Neuronal Terminals 
METH treatment can cause acute increases in both DA and 5-HT release, because 
of the action of the drug on DAT and 5-HT transporters (SERT). METH is known to be a 
substrate for both transporters and is transported into the axon terminal [24, 25]. After its 
intracellular transport (transporter- or diffusion-mediated) into the terminal, METH 
disrupts the storage vesicle proton gradient and causes the release of DA and 5-HT from 
vesicular compartments into the cytoplasm [26]. Cytoplasmic monoamine concentrations 
and DA release can be affected by METH via alteration of the function of the vesicular 
monoamine transporter (VMAT-2) [27, 28]. The directionality of the DA and 5-HT 
transporters can be reversed by increasing cytoplasmic DA and 5-HT levels, and causes 
significant, action potential-independent neurotransmitter efflux [29]. Short-term 
decreases in neurotransmitter reuptake also contribute to increases in extracellular DA 
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levels [30]. In addition, METH causes acute increases in striatal GLU levels via D1 
receptor-mediated disinhibition of corticostriatal GLU release [31].  
Binge METH administration is an established drug regimen causing neurotoxicity 
that includes degeneration of DAergic and 5-HTergic terminals in the striatum, 
hippocampus, and prefrontal cortex of experimental animals [32, 33]. Acute effects of 
METH include persistent DA and 5-HT terminal damage, manifested by long-term 
decreases in DAergic and 5-HTergic markers, in the striatum, hippocampus, and prefrontal 
cortex [32, 33]. The damage associated with METH has been shown to persist for at least 
two years in rodents and non-human primates [34, 35]. The expression of certain 
neurochemical markers, such as tryptophan hydroxylase and tyrosine hydroxylase, which 
are the rate-limiting enzymes for 5-HT and DA respectively, decreases after METH 
treatment. There is also a decrease in DAT and SERT expression [33, 36]. Excepting tissue 
content and neurotransmitter proteins, histological signs of neuronal damage have been 
reported which include the presence of swollen and distorted nerve terminals [37, 38]. 
Chronic administration of high METH doses also leads to neurotoxicity. Long-term METH 
abuse, which can damage DA and 5-HT nerve terminals, is associated with deficits in 
neuropsychological test performance, and it has been estimated that 40% of METH users 
display abnormalities on neuropsychiatric tests [39]. Chronic METH exposure converges 
to produce neuronal damage and inflammation [20]. A persistent reduction in most DA 
markers [13, 40] and SERT [41]  has also been observed in human chronic METH users. 
1.2.2. METH and Neuronal Apoptosis 
There is some supporting evidence indicating that METH may induce apoptosis or 
even cell death in some neuronal populations, in addition to damaging DA and 5-HT 
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terminals [42]. Apoptosis is a cell suicide program that is initiated after exposure to 
cytotoxic stressors, including UV, IR irradiation, chemotherapeutic drugs, and hypoxia. 
The marker for apoptotic cell death, Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL), increases in the striatum after exposure to METH [42, 43]. Importantly, 
METH administration affects brain functions, such as long-term memory, integrative 
functions, and attention [44], conditions which reflect hippocampal degeneration. The 
hippocampus is an important area in the temporal lobe of the brain. It plays a role in 
cognitive function including short-term memory, motivation, and emotional responses. 
Hippocampal degeneration has been observed in animals after exposure to high-dose 
METH [45]. METH-induced cell death was reported in the cortex, hippocampus, and 
hippocampal remnants [46]. Some papers have demonstrated cell death of calbindin-
containing GABA interneurons within the hippocampus in animal models [45, 47]. In the 
striatum, METH causes apoptosis in neurons post-synaptic to striatal monoaminergic 
terminals [46, 48, 49]. The apoptotic cells have been identified in subpopulations of 
GABA-interneurons, such al parvalbumin-containing striatal GABA interneurons [44]. 
METH-induced apoptosis in neuronal cell bodies is associated with mitochondrial damage 
and endoplasmic reticulum stress [42]. At the same time, METH causes DNA damage and 
alterations in the expression of Bcl-2 related genes, which may contribute to cell death in 
GABA interneurons [50]. METH can also induce apoptosis through increases in caspase-
3 activity and the Fas/FasL cell death pathway [51]. 
1.2.3. METH and Inflammatory Response 
METH has been reported to trigger inflammatory responses in areas where DA and 
5-HT terminals are damaged. METH elicits microglial activation in rat and mouse striati 
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[52, 53], rat cortices (including somatosensory and frontal cortices) [45, 54] and 
hippocampi [55]. Moreover, METH can trigger the release of some pro-inflammatory 
cytokines, which can lead to glial dysfunction as well as neuronal death [55, 56]. METH 
also induces reactive gliosis supported by the  observation of increased glial fibrillary 
acidic protein (GFAP) immunoreactivity in the striatum [57], hippocampus,  and indusium 
griseum [58]. Reactive gliosis is considered to be a universal reaction of injury in the CNS 
and is used as a specific marker of neuronal damage. 
METH-induced release of GLU also contributes to the activation of inflammatory 
mediators which enhance the METH toxicity to monoaminergic as well as non-
monoaminergic neurons [20]. For instance, GLU receptor activation is known to stimulate 
microglial activation whereas GLU antagonism suppresses the appearance of microglial 
activation [59]. Furthermore, during METH exposure, microglial activation and increases 
in GLU are seen in the striatum, prefrontal cortex, and hippocampus [60].  
1.2.4. METH and Oxidative Stress 
Reactive oxygen species are produced following METH exposure through 
numerous mechanisms. When cytoplasmic DA increases following exposure to 
pharmacologically relevant METH levels [61], DA-dependent oxidative stress has been 
observed due to DA autoxidation [62]. Dopamine can also cause oxidative stress via its 
metabolism by monoamine oxidase (MAO) which can induce the generation of superoxide 
and hydrogen peroxide free radicals [63]. Hydrogen peroxide can react with iron via the 
Fenton reaction and generate hydroxyl radicals, which are highly reactive and can result in 
damage by causing DNA mutations, lipid peroxidation, and modification of certain amino 
acids [64]. Damage to lipids and proteins causes DAergic terminal loss. Moreover, METH 
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exposure can cause oxidative stress because it can increase nitric oxide synthase activity 
and consequently increase the reactive nitrogen species [65]. Impairment of mitochondrial 
function has also been linked to pathways generating ROS, which can lead to an oxidized 
environment and decreased ATP production [66]. Oxidative stress can be further enhanced 
by dysfunction of antioxidant enzymes [67]. Enzymatic antioxidant defenses (e.g. catalase, 
superoxide peroxidases, and enzymes of the glutathione antioxidant system) serve to 
counterbalance the effect of oxidants such as hydrogen peroxide, hydroxyl radical, and 
superoxide radical. The activity of glutathione peroxidase (GPx) depends on the 
availability of reduced glutathione (GSH), which is the most important non-enzymatic 
antioxidant [68]. Antioxidant treatments have been shown to be neuroprotective against 
the damage produced by METH. This finding substantiates the significant contribution of 
oxidative stress to the neurotoxicity of amphetamines [69]. 
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Figure 1.2. Oxidative stress in METH toxicity. As high levels of METH enter the 
DAergic terminal, DA is released from storage vesicles, and triggers the generation of 
many reactive oxygen species (ROS). High-dose METH also enhances the release of 
glutamate in the striatum, leading to excitotoxicity. The generation of ROS and 
excitotoxicity can increase the oxidative stress, which enhances the METH-induced 
neurotoxicity. 
1.2.4. Markers for Apoptosis and Oxidative Stress 
Apoptosis is a programmed cell death. Caspases are the central mediators of this 
process. In mammals, caspases involved in apoptotic responses are classified into two 
groups according to their function and structure. The first group is termed initiator caspases 
(caspase-2, 8, 9, 10) that contain N-terminal adapter domains that allow for auto-cleavage 
and activation of downstream caspases. The second group is termed effector or executioner 
caspases (caspase-3, 6, 7) that lack of N-terminal adapter domains and are cleaved and 
activated by initiator caspases [70]. Caspases-3 and 7 are critical mediators of 
mitochondrial dysfunction-mediated apoptosis. For example, they can amplify the initial 
death signal by promoting cytochrome c release [71]. Under intrinsic stress, cleaved 
caspase-3 is produced via cleavage of caspase-9, which is considered to be the marker of 
middle stage apoptosis. 
Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme, has a particularly well-
researched role in base excision repair [72].  In addition to being involved in DNA repair, 
PARP is also directly involved in both apoptosis and necrosis [73, 74]. Caspase-3 can 
cleave PARP, and thus inactivate and inhibit PARP's DNA-repairing abilities. 
Therefore, cleaved PARP may be considered a marker of late apoptosis [75]. 
1.2.5. Antioxidant Mechanisms in the Brain 
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The brain has a high rate of aerobic metabolism, therefore it is one of the major 
organs generating large amounts of ROS and is especially susceptible to oxidative stress. 
GSH plays a critical role as an antioxidant in the brain due to its capability to scavenged 
multiple ROS [76]. GSH levels can increase or decrease after METH administration, 
depending on the severity of METH-induced oxidative stress [77-79]. Thus, changes in 
levels of GSH could be a sign of oxidative stress.  
1.2.6. METH Neurotoxicity in Experimental Animals vs. Humans 
As mentioned above, METH is a neurotoxic drug that causes deficits and alterations 
in central DAergic pathways. Repeated administration of METH in rodents has been shown 
to cause neurodegeneration of DAergic axon terminals in the striatum. The signs of METH-
induced neurodegeneration of DAergic axon terminals include reduced levels of DAergic 
markers, for example DAT, VMAT2, and TH as well as the levels of DA and its 
metabolites including: 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine (3-
MT) and homovanillic acid (HVA). These effects occur primarily in the striatum but are 
also seen in the cortex, thalamus, hypothalamus, and hippocampus [52, 80]. METH induces 
neurotoxicity in a dose-dependent manner [81]. METH has high popularity due to its wide 
availability, relatively low cost, and long duration of psychoactive effects. The neurotoxic 
effects of METH in humans are similar to those observed in experimental animals. For 
example, when administrated at high doses, METH can cause selective decreases in 
DAergic and 5-HTergic markers in both experimental animals and humans [82]. 
Neuroimaging studies of METH abusers have revealed reduction in striatal DAT levels 
that are associated with motor slowing and memory impairment [13, 83]. There is also a 
report demonstrating that METH alters dentate gyrus (DG) stem cell properties by delaying 
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the cell cycle and decreasing self-renewal capacities. DG neurogenesis impairment could 
be the mechanism of cognitive deficits verified in METH consumers [84]. These effects 
could be manifestations of METH-induced degeneration, however, growing evidence 
suggests that neuronal degeneration may not be a part of METH neurotoxicity in human 
METH users [85]. 
1.3. Transposable Elements and Long Interspersed Element 1 
1.3.1. METH and Epigenetic Changes 
Recently, epigenetics change has attracted much attention as a new and promising 
research area in METH abuse [86]. Several studies have reported that acute and chronic 
administration of METH can significantly influence the expression of many genes in the 
nucleus accumbens and dorsal striatum [87]. Recent reports show that the changes in 
histone modifications are related to the expression of genes coding for a variety of proteins 
that occur after self-administration of high-dose METH [87]. Moreover, decreased 
expression of several histone deacetylases (HDACs) occurs in the striatum after neurotoxic 
binge METH [88]. In the substantia nigra, high-dose METH injection over four days can 
decrease DNA methylation within the promoter region of alpha-synuclein [89].    
1.3.2. Transposable Elements and LINE-1 
Activation of transposable elements (TEs) is considered to be an epigenetic change 
[90]. Transposable elements are common and naturally occurring sources of genetic 
variation known to play diverse roles in genome evolution [91]. However, there are very 
few studies that have investigated the effects of METH on TEs in vivo. Among all TEs, 
long interspersed element 1 (LINE-1) is the most abundant and active endogenous 
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retroelement, accounting for 17% of the human genome [92, 93]. There are thousands of 
copies of LINE-1 in a single human cell, and most of them are silenced under normal 
physiological conditions. In the human genome, 80–100 copies of LINE-1 are capable of 
retrotransposition [94], and 10% of these are highly active via the copy and paste 
mechanism that involves an RNA intermediate and reverse transcriptase activity [95] 
(Figure 1.4). A complete cycle of LINE-1 retrotransposition can be associated with DNA 
inversions, duplications, or insertions [96]. LINE-1 is 6 kb in length and consists of a 
promoter, two open reading frames (ORF-1 and ORF-2), and a poly(A) tail [93, 97] 
(Figure1.4). ORF-1 is a basic protein with a nucleic acid chaperone and RNA binding 
activity. It is present within cytoplasmic ribonucleoprotein complexes or stress granules in 
the cytoplasm [98, 99]. ORF-2 has dual functions of endonuclease [100] and reverse 
transcriptase [101]. ORF-1 and ORF-2 mediate LINE-1 retrotransposition, which proceeds 
through three steps: transcription, reverse transcription, and insertion of the new 
synthesized DNA into the host genome via target site-primed reverse transcription [93, 
102]. According to the literature, LINE-1 can be expressed and undergo retrotransposition 
at a high frequency in the mammalian nervous system [103, 104]. Furthermore, 
deregulation of LINE-1 retrotransposition is involved in some neurological diseases such 
as Rett syndrome and ataxia telangiectasia [104]. Since LINE-1 retrotransposition can 
change cellular properties by causing gene deletions [105], DNA damage [102], apoptosis 
[106], and immune response [107], deregulation of LINE-1 in somatic cells is likely to 
occur as either a cause or a consequence of a disease. Our lab has shown that binge METH 
increases ORF-2 protein levels in the neurogenic zones of rat brains [86]. In neuronal cell 
lines, METH has been shown to trigger retrotransposition of LINE-1 [108].  
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Figure 1.3. LINE-1 structure and activation. LINE-1 is 6 kb in length and consists of a 
promoter, two open reading frames (ORF-1 and ORF-2) and a poly(A) tail. ORF-1 and 
ORF-2 mediate LINE-1 retrotransposition, which proceeds through 3 steps: transcription, 
reverse transcription, and insertion of the new synthesized DNA into the host genome via 
target site-primed reverse transcription. 
1.4. Neurogenic Zones and Neurogenesis 
1.4.1. Neurogenesis 
The dogma that the adult mammalian brain does not generate new neurons has been 
overturned [109]. It has been reported that thousands of new neurons are generated every 
day in an adult mammalian brain [110]. Adult neurogenesis is a process of generating 
functional neural cell types from neural stem cells and progenitor cells; it is important for 
the maintenance of brain integrity and optimal function [111]. This process occurs in two 
separate areas of the adult mammalian brain, the subgranular zone (SGZ) and the 
subventricular zone (SVZ) [111-113]. In the SGZ of the DG in the hippocampus, adult 
neural stem cells undergo proliferation, fate specification, maturation, migration, and 
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eventual integration into the pre-existing neural circuitry within the hippocampus [114, 
115]. Principal DG cells are the only neuronal subtype that is generated, and newly 
generated neurons have distinct properties that enable them to contribute to specialized 
functions in learning and memory [116]. Subventricular zone neurogenesis is related to 
olfactory bulb formation [117] and may represent a potential source of cells used to repair 
damaged brain tissue [118]. In the SVZ of the lateral ventricle, adult neural stem cells give 
rise to glia and neuroblasts [117]. These neuroblasts migrate over a long distance to the 
olfactory bulb and differentiate into local interneurons that have various functions in 
olfaction. 
The SGZ is located in the hippocampus between the hilus and the granule cell layer 
of the DG (Figure 1.5). Previous studies have shown that after newborn neurons mature 
and migrate from the granule layer in the adult DG, they form axonal projections and reach 
the CA3 [119]. There are main four types of cells in the SGZ. Type-1 cells (radial-glia-like 
stem cells) have astrocyte characteristics and they express GFAP and nestin [120, 121]. 
Type-1 cells divide asymmetrically. They can either proliferate to other Type-1 cells to 
maintain their own population or differentiate into the intermediate cells, called type-2 cells 
(neural progenitor cells, 2a and 2b). Type-2 cells generate the migratory neuroblasts known 
as type-3 cells. Type-3 cells migrate into the granule cell layer and differentiate into granule 
neurons. Type-4 cells, after having ceased mitosis, extend axons toward the CA3, leading 
to the development of mature neurons which are positive for neuronal specific nuclear 
protein (NeuN) and calbindin. Type-4 cells integrate with the mossy fiber pathway [122].  
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Figure 1.4. Neurogenesis in the subgranular zone (SGZ). Top panel: type-1 cells 
generate type-2 cells that, in turn, generate type-3 cells; type-3 cells generate immature 
neurons that finally become mature neurons. Bottom panel: a sequence of cell types 
involved in neuronal lineage and specific markers allowing cell identification are presented.  
The SVZ is a second site of neurogenesis in the adult brain. New neurons formed 
in this region constantly migrate toward the olfactory bulb to replace interneurons [123]. 
In the olfactory bulb of adult rats, approximately 80,000 new granular neurons are formed 
each day from the SVZ progenitors [124]. The SVZ is formed by three main cell types: 
type A, B, and C cells. The type-A cells are migratory neuroblasts. Approximately 33% of 
the SVZ cells are type-A cells. They express doublecortin (DCX) and polysialylated 
neuronal cell adhesion molecule (PSA-NCAM). They migrate through the rostral 
migratory stream (RMS) to the olfactory bulb where they differentiate into granular and 
glomerular neurons. In the SVZ, about 23% of cells are type-B cells, which give rise to 
type-C cells. Type-B cells are slow proliferating multipotent cells expressing GFAP. They 
have the characteristics of astrocytes and can be classified as B1 and B2 cells. B1 cells are 
in contact with the lateral ventricle lumen and have a small apical surface, a single basal 
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body, and a single short primary cilium. The Type-C cells are transit-amplifying immature 
precursor cells that account for about 11% of the SVZ cells. They produce type-A cells and 
express the transcription factor distal-less homeobox 2 (Dlx2) [124] and nestin [125]. 
1.4.2. Markers for Neurogenesis in the Neurogenic Zones 
In this study, we used specific markers to differentiate diverse cell types. The 
specific markers include: (a) Proliferating cells: Ki-67 is a nuclear protein expressed in 
dividing cells for the entire duration of their mitotic activity, the expression of which is 
neither linked to DNA repair nor to apoptotic processes. Therefore, it is used as a reliable 
marker for proliferating cells) [126, 127]; (b) Immature neurons: DCX can encode a 
microtubule-associated protein expressed in migrating neuroblasts therefore it can serve as 
a marker of immature neurons [128]; (c) Mature neurons: NeuN, a neuronal specific 
nuclear protein, is the most frequently used specific marker for mature neurons [129]. 
Another common marker for mature neurons is microtubule-associated protein (MAP-2). 
(d) Astrocytes: GFAP is a common marker for astrocytes [125]. 
The cell composition of the SGZ and SVZ and their markers are presented in Figure 
1.5 and Figure 1.6, respectively. 
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Figure 1.5. Neurogenesis in the subventricular zone (SVZ).  Top panel: a sagittal view 
of a rodent brain showing the sites of neurogenesis in the SVZ/olfactory (OB) system. Cells 
that proliferate in the SVZ migrate along the rostral migratory stream (RMS) to reach the 
OB, where they migrate radially and undergo terminal differentiation. Bottom panel: a 
sequence of cell types involved in neuronal lineage and specific markers allowing cell 
identification are presented. Markers appearing in bold are specific to each stage. 
1.4.3. METH effects in the neurogenic zones 
METH abuse in humans severely damages the hippocampus, for example by 
reducing hippocampal volume and producing hippocampal-dependent memory deficits 
[130]. As stated previously, adult neurogenesis has been demonstrated in the hippocampal 
SGZ [131]. Recently,  it has been shown that a number of external factors, such as drug 
abuse can regulate the birth, survival, and fate of newly-generated SGZ progenitors [132]. 
METH has been reported to dysregulate neurogenesis and induce apoptosis in the 
hippocampus and often leads to the death of pyramidal neurons and granular cells [133, 
134]. Intermittent (occasional access) and daily (limited and extended access) self-
administration of METH can have an impact on different aspects of hippocampal 
neurogenesis [134]. According to a study aiming to clarify the effect of METH on SVZ 
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stem/progenitor cell dynamics and neurogenesis, high dosages of METH triggered cell 
death both by necrosis and apoptosis, and inhibited the proliferation of progenitor cells in 
the SVZ. Furthermore, another study reported that, at non-toxic concentrations, METH 
treatment decreased neuronal differentiation and maturation [135]. 
1.5. Rationale, Objective, and Hypotheses  
In our previous study, we found that binge METH increased expression of ORF-2 
in the neurogenic zones in rat brains and that some of the ORF-2-positive neurons were 
also positive for DCX. But we did not identify all cell types that showed increased ORF-2 
levels after METH administration. Additionally, we did not determine the potential 
functions of increased ORF-2. The major objective of the current study is to differentiate 
the cell populations expressing ORF-2 and to discover whether upregulation of ORF-2 is 
associated with oxidative stress and/or apoptosis in the neurogenic zones after exposure to 
binge METH.  
Our previous study showed that METH can activate LINE-1 in vivo, and trigger 
retrotransposition of LINE-1 in vitro [108]. Moreover, TEs undergo retrotransposition 
mostly in proliferating cells [135], LINE-1 activation can lead to DNA breakage suggesting 
that LINE-1 may cause apoptosis. It has been reported that binge METH induces apoptosis 
in the neurogenic zones. Cytoplasmic and extracellular DA levels increase dramatically 
after METH exposure [61], which lead to increased ROS production and oxidative stress 
[65]. Furthermore, METH-induced increases in GLU release cause mitochondrial 
dysfunction thus further potentiating oxidative stress [136]. On the base of these 
knowledges, we hypothesized that neurotoxic binge METH would activate LINE-1 in 
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proliferating cells in the neurogenic zones and the METH-induced increases in LINE-1 
activity would be associated with apoptosis and oxidative stress.  
 
CHAPTER 2: MATERIALS AND METHODS  
2.1. Animals 
Adult male Sprague-Dawley rats (weighing 250–300g) were accommodated in a 
pair-housed, humidity-controlled room and temperature-controlled (20–22 °C). Food and 
water were provided. We allowed all the rats to acclimatize for seven days before we start 
the research. Our animal procedures have been approved by the Institutional Animal Care 
and Use Committee (IACUC) at Wayne State University. All the animal procedures were 
conducted between 7:00 A.M. and 7:00 P.M. in strict accordance with the National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory. The description of 
animal procedures meets the ARRIVE recommended guidelines described by The National 
Centre for the Replacement, Refinement, and Reduction of Animals in Research. 
2.2 Drug Treatment 
(+)-METH hydrochloride (METH, 10 mg/kg free base) (Sigma-Aldrich, St. Louis, 
MO) or saline (1 mL/kg) was administered to the rats every 2 h in four successive 
intraperitoneal (i.p.) injections. We measured the core body temperatures of the rats before 
the starting of saline/ METH administration and the core body temperatures at 1 hour after 
each injection and sacrifice the rats 24 hours after the last injection of saline/ METH. 
2.3. Tissue Collection and Storage 
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We removed the brain from rats and washed with ice-cold phosphate-buffered 
saline (PBS). The brains were fixed in 4% paraformaldehyde for 24 h at 4°C. After fixation, 
the brains were incubated in 20% and then in 30% glycerol in PBS (24 h in each solution 
at 4 °C). Subsequently, the brains were snap-frozen and stored at − 80 °C until assayed.  
2.4. Tissue Immunohistochemistry 
We checked the protein level via immunofluorescence technique. We used the 
tissue sections (40 μm) from the SVZ (1.16 to 0.28 according to Bregma) and the SGZ  (−
3.14 to –4.66 according to Bregma). We permeabilized the tissue sections with PBS + 0.1% 
triton and did antigen retrieval using 1× citrate buffer for 30-45 min at 90°C. We blocked 
the tissue at room temperature using blocking buffer (PBS pH 7.4, 0.1% Triton X-100, and 
5% bovine serum albumin (BSA)) for 1 hours after cooled the sections to room temperature. 
The sections were then incubated overnight at 4°C with a chicken anti-ORF-2 antibody 
(1:200, Rockland Immunochemicals Inc., Limerick, PA) and a cell type marker antibody ,a 
rabbit anti-GFAP (1:200, Cell Signaling, Danvers, MA), rabbit anti-NeuN (1:400, Cell 
Signaling), rabbit anti-Ki-67 (1:100, Abcam, Cambridge, MA) or rabbit anti-doublecortin 
(1:100, Abcam) antibody or an apoptosis marker antibody (a rabbit anti-cleaved PARP 
(1:200, Abcam) or rabbit anti-cleaved caspase-3 (1:400, Cell Signaling) antibody. In the 
last experiment, the sections were double-labeled with the anti-ORF-2 antibody and mouse 
anti-GSH (1:200, Abcam) antibody. The next day, We washed the section with washing 
buffer (PBS pH 7.4, 0.1% Triton X-100, and 5% bovine serum albumin (BSA)) for three 
times (5 min per washing) and incubated the sections with secondary antibody, anti-
chicken Alexa-488 (1:1000) and anti-rabbit Alexa-594 (1:1000) (Life Technologies, 
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Carlsbad, CA) for 2 hours in room temperature. We stained the nuclei using DRAQ5 (Life 
Technologies). Lastly, we mounted the sections on slides using Flouromount mounting 
medium (Sigma-Aldrich) and cover the slips. We captured the images via Leica TCS SPE-
II confocal microscope under the 63 × oil objective. These images were then analyzed 
using Leica co-localization analysis software. The ORF-2 immunofluorescence was 
measured by Image J and averaged. Mean of the averages was then calculated for each rat. 
2.5. Cell Culture 
PC12 cells (a rat adrenal gland pheochromocytoma cell line) were cultured on 
sterilized coverslips (Warner Instrument, Hamden, CT) in the HyClone RPMI-1640 
medium (GE Healthcare Life Sciences) containing 5% fetal bovine serum (FBS) and 10% 
horse serum. The coverslips were placed in wells of a 24-well plate; each well was seeded 
with approximately 50,000 cells.  
2.6. Cultured Cells Immunocytochemistry 
The next day, the cells were treated with 2mM glutamic acid for 1h, 2h, 3h, 4h, 5h, 
6h, 12h or 24h at room temperature. Next, the cells were fixed in 4% paraformaldehyde for 
20 min and then permeablized using 0.1% Triton X-100 in PBS for 1h at room temperature. 
Subsequently, the cells were blocked in blocking buffer (0.1% Triton X-100, and 1% BSA 
in PBS) for 1h at room temperature and incubated overnight at 4°C with the chicken anti-
ORF-2 antibody (1:1000, Rockland Immunochemicals Inc.) or rabbit anti-cleaved caspase-
3 antibody (1:400, Cell Signaling). The next day, We washed the section with washing 
buffer (PBS pH 7.4, 0.1% Triton X-100, and 5% bovine serum albumin (BSA)) for three 
times (5 min per washing) and incubated the sections with secondary antibody, anti-
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chicken Alexa-488 (1:1000) and anti-rabbit Alexa-594 (1:1000) (Life Technologies, 
Carlsbad, CA) for 2 hours in room temperature. We stained the nuclei using DRAQ5 (Life 
Technologies). Lastly, we mounted the sections on slides using Flouromount mounting 
medium (Sigma-Aldrich) and cover the slips.  
2.7. Statistical Analysis 
We analyzed the data using two-way ANOVA (factors: regions and treatment) 
followed by Bonferroni post hoc test. Two-way repeated measures (RM) ANOVA was 
used for analysis of temperature data. Correlations between measured parameters were 
performed using Pearson’s correlation analysis. Significance was set at p < 0.05 (95% 
confidence interval) and we further analyzed data using GraphPad Prism program 
(GraphPad Software Inc., San Diego, CA, USA). 
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Chapter 3 RESULTS 
3.1. Binge METH Induces Hyperthermia 
In experimental rodents, high doses of METH are known to cause hyperthermia, 
which is one of the factors that mediate the neurotoxicity of the drug. An increased core 
body temperature can promote the METH induced neuro-toxicity, while a lower body 
temperature reduces the METH-induced toxicity [18, 20]. We measured the core body 
temperatures of the rats before the starting of saline/ METH administration (baseline 
temperatures) and the core body temperatures at 1 hour after each injection. As shown in 
Figure 3.1, a significant increase in body temperature was observed in METH-treated 
animals (**p<0.005, n=6, by two-way ANOVA followed by Bonferroni post hoc test). 
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Figure 3.1. Hyperthermia during binge METH treatment.  We observed a significant 
increase (F(4,50) = 4.97, **p < 0.005, n=6, by two-way ANOVA) in rat core body 
temperature. The two-way ANOVA showed a significant increase in core body 
temperature at 1 h (***p < 0.001, n = 6), 3 h (**p < 0.005, n = 6), 5 h and 7 h (*p < 0.05, 
n = 6) after binge METH. Abbreviations: h, hour(s); METH, methamphetamine. 
3.2. Binge METH Increases ORF-2 Protein Levels in Neurogenic Zones 
A previous study conducted in our lab showed that ORF-2 increased in the 
neurogenic zones at 24 hours after binge METH [3]. Therefore, we first examined rats’ 
brains for ORF-2 protein immunoreactivity in the SGZ and SVZ (average of 3 locations 
outlined in Fig. 3.2). Similar to previous results, low ORF-2 protein immunoreactivity was 
observed in neurogenic zones in the saline-treated rats, while significantly higher ORF-2 
protein immunoreactivity was detected in both the SGZ and SVZ in METH-treated rats 
(Fig. 3.3) (+75.5%, ***p< 0.001 and +125%, ***p< 0.001, respectively, n=6, by two-way 
ANOVA followed by Bonferroni post hoc test), thus confirming the results of our previous 
study. 
 
Figure 3.2. A schematic illustration of the subgranular zone (SGZ) and 
subventricular zone (SVZ).  In the adult rodent brain, (a) the SGZ lies below the granular 
cell layer of the DG whereas (b) the SVZ lies between the lateral ventricle and the striatum, 
as shown by red markers. Representative images were taken from these 3 regions of the 
SGZ (a) and the SVZ (b) per condition (saline vs. METH). 
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Figure 3.3. Binge METH increases immunoreactivity of ORF-2 in the neurogenic 
zones.  Shown are representative images taken from 3 regions of the SGZ (A) and the SVZ 
(B). The two-way ANOVA showed significant effect in ORF-2 signal (green) of treatment 
(F(1,20) = 13.7, **p < 0.005, n=6) & region (F(1,20) = 128, ***p < 0.001, n=6). Bonferroni 
post-tests revealed a significant increase in ORF-2 in both SGZ and SVZ between treatment 
(+75.5%, ***p < 0.001, and +125%, ***p < 0.001, n=6). Bonferroni post-tests revealed 
significant decrease in ORF-2 in the saline-treated group but not the METH-treated group 
between regions (-31.9%, ***p < 0.001, and -9.02%, ***p < 0.001, respectively, n=6). The 
data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, 
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone; 
SVZ, subventricular zone.  
3.3. Identification of Cell Types Expressing Activated LINE-1 in the 
Neurogenic Zones after Binge METH 
3.3.1. Intermediate progenitor cells and neuronal cells 
The intermediate progenitor cells include types 2a, 2b, and 3 cells within the SGZ 
and types A and C cells in the SVZ. The cells that proliferate rapidly within the SGZ are 
type 2 and some type 3 cells, whereas the cells that proliferate within the SVZ are type A 
and C cells. In the SGZ, type 2b and type 3 progenitor cells, as well as postmitotic immature 
neurons express DCX protein (Fig.3.6.A). Immature and mature neurons, but not the 
intermediate progenitor cells, can be identified by NeuN protein in this zone (Fig.3.7.A). 
In the SVZ, neuroblasts express DCX (Fig.3.6.B) while mature neurons express NeuN 
(Fig.3.7.B). MAP2, as a marker of neuronal cells, can be used for cytoskeleton staining.  
LINE-1 is activated and readily retrotransposes in proliferating cells. Therefore, we 
first tested whether binge METH would activate LINE-1 in cells proliferating within the 
neurogenic zones. We found that, compared to the saline group, binge METH treatment 
can slightly increase immunoreactivity of Ki-67, a marker of proliferating cells, in the SGZ 
and SVZ (+9.22%, p > 0.05 and +21.5%, *p < 0.05, respectively, n=6, by two-way 
ANOVA followed by Bonferroni post hoc test) at 24 hours after the last injection of the 
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drug (Fig. 3.4.A-C). We also found that some ORF-2 immunoreactivity co-localized with 
Ki-67 immunoreactivity (in the same compartment or cell type) in both saline and METH-
treated rats (Fig. 3.4.A-B). Statistically, METH treatment did not significantly change co-
localization of the ORF-2 signal with the Ki-67 signal in the SGZ and SVZ when assessed 
by Pearson’s correlation analysis (+42.2%, p > 0.05; +17.9%, p > 0.05, respectively, n=6, 
by two-way ANOVA followed by Bonferroni post hoc test) (Fig. 3.4.C.b). This finding 
was not surprising as Ki-67 localizes mainly in the nucleus while ORF-2 localizes primarily 
in the cytoplasm. Therefore, we next counted the cells that expressed both proteins 
regardless of the sub-cellular compartment. As compared to the saline controls, the METH-
treated rats expressed, on average, 19.2 cells (vs. 12.3 cells in saline group) that expressed 
both proteins in the SGZ, which was a 56.1% increase. In the SVZ, 7.63 cells (vs. 5.78 
cells in saline group), on average, expressed both proteins in METH-treated rats, which 
translated to a 32.0% increase compared to the saline control (Fig. 3.5). 
We used DCX as a marker of precursor (type-2b and type-3 cells) and immature 
neuronal cells to discover if neurotoxic binge METH could activate LINE-1 in any of these 
types of cells. As shown in our previous study [86], many but not all ORF-2-positive 
neurons were also positive for DCX in both the saline- and METH-treated rats (Fig.3.5). 
However, statistically, binge METH did not show a significant effect on the 
immunoreactivity of DCX in the SGZ and SVZ (+10.3%, p > 0.05, and +20.0%, p > 0.05, 
respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test) (Fig.3.6.A-
C). Similarly, binge METH did not affect the co-localization of the ORF-2 signal with 
DCX signal in the SGZ and SVZ (F(1,12) = 4.52, p > 0.05, n = 4, by two-way ANOVA)  
(Fig.3.6.C.b). In addition to proliferating precursor cells and immature neurons, there are 
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mature neuronal and glial cells within the neurogenic zones. Immunostaining for NeuN, a 
classic marker of postmitotic neurons, revealed binge METH significantly decreased the 
immunoreactivity of NeuN in the SGZ and SVZ (-15.31%, ***p<0.001 and -38.15%, 
*p<0.05, respectively, n=6, by two-way ANOVA followed by Bonferroni post hoc test) 
(Fig. 3.7.C.a). At the same time, binge METH increased co-localization of the ORF-2 
signal with the NeuN signal in the SGZ but not the SVZ compared to the saline group 
(+74.58%, **p<0.005, and +7.66%, p > 0.05, respectively, n=6, by two-way ANOVA 
followed by Bonferroni post hoc test) (Fig.3.7.b). 
The ORF-2 signal did not co-localize with the MAP2 (marker of neuronal cells) 
signal in the cytoskeleton outside the neurogenic zones (Fig.3.8). 
The result suggests that systemic administration of neurotoxic doses of binge 
METH increased the activity of LINE-1 in postmitotic neurons in the SGZ.  
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Figure 3.4.  Binge METH does not change immunoreactivity of Ki-67 in the 
neurogenic zones.  Representative images from 3 regions of the SGZ (A) and the SVZ (B) 
per condition (SAL and METH) were taken. The Ki-67 protein signals (pink) showed 
increase in METH-treated rats compared to the saline-treated rats The two-way ANOVA 
showed significant effect in Ki-67 signal of treatment (F(1,20) = 6.40, *p < 0.05, n=6) and 
region (F(1,20) = 7.37, *p < 0.05, n=6). Bonferroni post-tests did not reveal significant 
difference in Ki-67 in SGZ but showed a significant increase in SVZ between treatment 
(+9.22%, p > 0.05, and +21.5%, *p < 0.05, respectively, n=6). Bonferroni post-tests 
revealed a significant increase in Ki-67 in the saline-treated group but not the METH-
treated group between SGZ and SVZ (+10.4%, *p < 0.05, and +22.8%, p > 0.05, 
respectively, n=6). Some ORF-2-positive neurons (green) are positive for Ki-67 (arrows), 
which is a selective marker of proliferating cells, in both saline- and METH-treated rats. 
METH does not change co-localization of ORF-2 signal with Ki-67 signal in neurogenic 
zones. The two-way ANOVA did not show significant effect in co-localization of ORF-2 
and Ki-67 of treatment (F(1,20) = 2.47, p > 0.05, n=6) & region (F(1,20) = 3.72, p > 0.05, 
n=6).  The data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, 
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone; 
SVZ, subventricular zone. 
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Figure 3.5. Number of cells expressing both ORF-2 immunoreactivity and Ki-67 
immunoreactivity. The two-way ANOVA showed significant effect in number of cells 
that express both ORF-2 and Ki-67 of treatment (F(1,20) = 49.2, ***p<0.001, n=6) and 
region (F(1,20) = 11.6, **p < 0.05, n=6). Bonferroni posttests revealed a significant 
increase in SGZ but not SVZ between treatment (+56.1%, **p < 0.005, and +32.0%, p > 
0.05, n=6). Bonferroni posttests revealed a significant increase in the saline-treated group 
and the METH-treated group between regions (-53.0%, **p < 0.005, and -60.3%, ***p < 
0.001, respectively, n=6). Nuclei are depicted in blue. Abbreviations: METH, 
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone; 
SVZ, subventricular zone. 
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Figure 3.6. Binge METH has no effect on the immunoreactivity of DCX in the 
neurogenic zones.  Representative images from 3 regions of the SGZ (A) and the SVZ (B) 
per condition (saline and METH) were taken. The two-way ANOVA showed a significant 
effect in DCX signal (red) of treatment (F(1,12) = 11.3, *p < 0.05, n=4), but did not show 
significant effect in DCX signal of region (F(1,12) = 1.01, p > 0.05, n=4). Bonferroni 
posttests didn`t reveal significant difference in DCX signal in neither SGZ nor SVZ 
between treatment (+10.3%, p > 0.05, and +20.0%, p > 0.05, respectively, n=4)Some ORF-
2-positive neurons (green) are also positive for DCX (arrows), which is a selective marker 
of immature and type-3 cells, in both the saline- and METH-treated rats. METH does not 
change co-localization of ORF-2 signal with DCX signal in the neurogenic zones The two-
way ANOVA did not show significant effect in co-localization of ORF-2 and DCX of 
treatment (F(1,12) = 4.52, p > 0.05, n=4), but it showed a significant increase in region 
(F(1,12) = 7.08, *p < 0.05, n=4). Bonferroni posttests didn`t reveal significant difference 
in DCX signal (red) in neither SGZ nor SVZ between treatment (+10.3%, p > 0.05, and 
+20.0%, p > 0.05, respectively, n=4). . The data are summarized in (C). Nuclei are depicted 
in blue. Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open reading 
frame 2; SGZ, subgranular zone; SVZ, subventricular zone. 
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Figure 3.7. Binge METH decreases the immunoreactivity of NeuN in the SGZ.  
Representative images from 3 regions of the SGZ (A) and the SVZ (B) per condition (saline 
and METH) were taken. The two-way ANOVA showed significant effect in NeuN signal 
(pink) of treatment (F(1,20) = 1378, ***p < 0.001, n=6) and region (F(1,20) = 40.0, *p < 
0.05, n=6). Bonferroni posttests revealed a significant decrease in NeuN signal (pink) in 
SGZ and SVZ between treatment (-15.31%, ***p < 0.001 and -38.15%, *p < 0.05, 
respectively, n=6). Bonferroni posttests revealed a significant decrease in NeuN signal in 
the saline-treated group and the METH-treated group between SGZ and SVZ (-83.2%, 
***p < 0.001 and -76.7%, ***p < 0.001, respectively, n=6).Some of ORF-2-positive 
neurons (green) are also positive for NeuN (arrows), a selective marker of mature neurons, 
in both the saline- and METH-treated rats. The two-way ANOVA showed a significant 
increase in co-localization of ORF-2 and NeuN of treatment (F(1,20) = 77.1, ***p < 0.001, 
n=6), and region (F(1,20) = 15.00, ***p < 0.001, n=6). Bonferroni posttests revealed 
significant increase in co-localization between ORF-2 and NeuN in SGZ but not SVZ after 
binge METH (+74.58%, **p < 0.005, and +7.66%, p > 0.05, respectively, n=6). Bonferroni 
posttests revealed significant increase in co-localization in the saline-treated group and the 
METH-treated group between regions (+152%, ***p < 0.001 and +72.0%, ***p < 0.001, 
respectively, n=6). The data are summarized in (C). Nuclei are depicted in blue. 
Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open reading frame; SGZ, 
subgranular zone; SVZ, subventricular zone. 
 
Figure 3.8. The ORF-2 signal does not co-localize with the MAP2 signal in 
cytoskeleton outside the neurogenic zones.  METH (10 mg/kg free base) was 
administered to young adult male Sprague-Dawley rats every 2h in four successive 
intraperitoneal (i.p.) injections and the rats were killed 24h later. The ORF-2 signal (green) 
does not co-localize with the MAP2 signal (red) outside the SGZ (A) or SVZ (B) after 
METH treatment. 
3.3.2. Radial glial-like stem cells and mature glial cells 
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Radial glia-like stem cells and mature glia both express GFAP protein; however, 
they differ in localization and shape. In the SGZ, radial glia-like cells reside at the bottom 
of the zone (adjacent to the hilus) and have small cell bodies with short processes, while 
mature glia reside mostly at the top and outside of the zone and are star-shaped with long 
processes (Fig.3.10). In the SVZ, radial glia-like cells are mostly located adjacent to the 
ventricle, while the majority of mature glia localize close to the striatum. 
We have detected that binge METH increased the immunoreactivity of GFAP in 
the SGZ and SVZ and their immediate proximity (+44.6%, **p < 0.005 and +120%, ***p 
< 0.001, respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test). 
We also observed that most of the ORF-2 immunoreactivity co-localizes with GFAP 
immunoreactivity in both zones and METH treatment significantly increased the co-
localization of both SGZ and SVZ (+85.3%, ***p < 0.001 and +130%, ***p < 0.001, 
respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test.) (Fig.3.9). 
The ORF-2 signal co-localized with the GFAP signal in both radial and mature glia in the 
DG (Fig.3.10).  
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Figure 3.9. Binge METH increases immunoreactivity of GFAP in the neurogenic 
zones.  Representative images from 3 regions of the SGZ (A) and the SVZ (B) per 
condition (saline and METH) were taken. The two-way ANOVA showed a significant 
increase in GFAP signal (red) of treatment (F(1,12) = 1.99, ***p < 0.001, n=4) but not 
region (F(1,12) = 63.7, p > 0.05, n=4). Bonferroni posttests revealed a significant increase 
in GFAP signal in SGZ and SVZ between treatment (+44.6%, **p < 0.005 and +120%, 
***p < 0.001, respectively, n=4). ORF-2-positive neurons (green) are also positive for 
GFAP (arrows), which is a selective marker of radio-glial-like and mature glial cells, in 
both the saline- and METH-treated rats. The two-way ANOVA showed a significant 
increase in co-localization of ORF-2 and GFAP of treatment (F(1,12) = 27.9, ***p < 0.001, 
n=4), and region (F(1,12) = 201, ***p < 0.001, n=4). Bonferroni posttests revealed a 
significant increase in co-localization between ORF-2 and GFAP in SGZ and SVZ after 
binge METH (+85.3%, ***p < 0.001, and +130%, ***p < 0.001, respectively, n=4). 
Bonferroni posttests did not reveal significant difference in co-localization in the saline-
treated group between regions. But it showed a significant increase in the METH-treated 
group between SGZ and SVZ (+12.6%, p > 0.05 and +40.0%, ***p < 0.001, respectively, 
n=4). The data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, 
methamphetamine; SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ, 
subventricular zone. 
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Figure 3.10.  The ORF-2 signal co-localizes with the GFAP signal in different types of 
glial cells of the SGZ after METH exposure.  METH (10 mg/kg free base) was 
administered to young adult male Sprague-Dawley rats every 2h in four successive 
intraperitoneal (i.p.) injections and the rats were killed 24h later. ORF-2 signal (green) 
signal co-localize with GFAP signal (red) in both mature glial cells (A) and radio-glial cells 
(B). 
 
3.4. The Role of LINE-1 in the Neurogenic Zones 
So far, we have demonstrated that systemic administration of neurotoxic doses of 
binge METH increases the activity of LINE-1 in glial cells and postmitotic cells in the 
neurogenic zones. We further investigated the role of increased ORF-2 in these types of 
cells. As mentioned before, administration of high doses of METH can cause oxidative 
stress, inflammatory response, and neuronal apoptosis, which lead to damage of DAergic 
and 5HTergic neuronal terminals (neurotoxicity). [137]. We would like to determine 
whether binge METH-induced increase of LINE-1-encoded ORF-2 protein is associated 
with apoptosis and/or oxidative stress. Therefore, we next stained the tissue using the 
markers specific for different stages of apoptosis and oxidative stress. We found that binge 
METH significantly increased immunoreactivity of cleaved caspase-3, which localized 
mostly in the nucleus, in the SGZ and SVZ (+71.4%, ***p < 0.001 and +92.3%, ***p < 
0.001, respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test). This 
result was consistent with the existing knowledge that exposure to a high dose of METH 
induces apoptosis. Moreover, METH treatment can significantly increase the co-
localization of ORF-2 immunoreactivity and cleaved caspase-3 immunoreactivity in the 
SGZ and SVZ (+25.2%, p > 0.05 and +68.42%, ***p < 0.001, respectively, n=4, by two-
way ANOVA followed by Bonferroni post hoc test) compared to saline controls (Fig.3.11). 
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Commonly, cleaved caspse-3 localize in the cytoplasm. To verify the reliability of the 
cleaved caspase-3 antibody, we treated PC12 cells with glutamic, an acid-stress factor, and 
stained the cells with cleaved caspase-3 antibody.  The cleaved caspase-3 was observed in 
the cytoplasm (Fig.3.12). Subsequently, we used cleaved PARP as a marker of late stage 
apoptosis and found that METH did not significantly increase the signal of cleaved PARP 
in the SGZ and SVZ (+22.3%, p > 0.05 and +18.7%, p > 0.05 respectively, n=6, two-way 
ANOVA followed by Bonferroni post hoc test). Furthermore, METH treatment did not 
change the co-localization of the ORF-2 signal and cleaved PARP signal in the SGZ and 
SVZ (F(1,20) = 0.113, p > 0.05, n = 6, by two-way ANOVA) (Figure 3.13). We also 
performed a triple staining study and found that the ORF-2 signal co-localizes with the 
cleaved-PARP signal in few immature (Figure 3.14) and proliferating (Figure 3.15) neuron 
cells within the neurogenic zones. All these results show that the ORF-2 signal co-localizes 
with some, but not all, apoptotic markers within the neurogenic zones after METH 
treatment, suggesting that METH-induced increases in ORF-2 may not be associated with 
apoptosis.  
An increased level of GSH often indicates an adaptive response to oxidative stress. 
Interestingly, we found that binge METH significantly increased immunoreactivity of GSH 
in the SGZ and SVZ (+28.4%, *p < 0.05 and +46.9%, p > 0.05n = 6, by two-way ANOVA 
followed by Bonferroni post hoc test). METH also significantly increased co-localization 
of ORF-2 with GSH in the SGZ and SVZ (+24.6%, ***p < 0.001and +57.7%, ***p < 0.001, 
respectively, n = 6, by two-way ANOVA followed by Bonferroni post hoc test) (Figure 
3.16). Our data also showed that the ORF-2 signal co-localized with the GSH signal in 
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most cells within the neurogenic zones. We can conclude that binge METH-induced 
increase of ORF-2 may be associated with responses to oxidative stress.  
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Figure 3.8. Binge METH increases immunoreactivity of cleaved caspase-3 and ORF-
2 immunoreactivity co-localizes with cleaved caspase-3 immunoreactivity in the 
neurogenic zones.  Representative images from 3 regions of the SGZ (A) and the SVZ (B) 
(saline and METH) were taken. The two-way ANOVA showed a significant increase in 
cleaved caspase-3 signal (pink) of treatment (F(1,12) = 87.8, ***p < 0.001, n=4) but not 
region (F(1,12) = 4.18, p > 0.05, n=4). Bonferroni posttests revealed a significant increase 
in cleaved caspase-3 signal in SGZ and SVZ between treatment (+71.4%, ***p < 0.001 
and +92.3%, ***p < 0.001, respectively, n=4).ORF-2-positive neurons (green) are also 
positive for cleaved caspase-3 (arrows), a selective marker of middle stage of apoptosis, in 
both the saline- and METH-treated rats. The two-way ANOVA showed a significant 
increase in co-localization of ORF-2 and cleaved caspase-3 of treatment (F(1,12) = 12.4, 
**p < 0.005, n=4), and region (F(1,12) =  24.8, ***p < 0.001, n=4). Bonferroni posttests 
did not reveal significant increase in co-localization between ORF-2 and cleaved caspase-
3 in SGZ but showed a significant increase in SVZ after binge METH (+25.2%, p > 0.05, 
and +68.4%, ***p < 0.001, respectively, n=4). Bonferroni posttests did not reveal 
significant difference co-localization of ORF-2 and cleaved caspase-3 in co-localization in 
saline between regions. But it showed a significant increase in METH between SGZ and 
SVZ (+18.7%, p > 0.05 and +50.3%, **p < 0.005, respectively, n=4).The data are 
summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, methamphetamine; 
SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ, subventricular 
zone. 
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Figure 3.9. Cleaved caspase-3 immunoreactivity in PC12 cells.   Cells were treated with 
2mM glutamic acid for 4h (right) & untreated cells (left). After glutamic acid treatment, 
 
46 
cleaved caspase-3 (green) increases in the cytoplasm. 
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Figure 3.10. Binge METH increases immunoreactivity of cleaved PARP.  ORF-2 signal 
co-localizes with cleaved PARP signal in the SVZ. Representative images from 3 regions 
of the SGZ (A) and the SVZ (B) (as shown in Figure3.2) per condition (saline (a) and 
METH (b)) were taken. The two-way ANOVA showed a significant increase in cleaved 
PARP signal (red) of treatment (F(1,20) = 28.8, ***p < 0.001, n=6) and region (F(1,20) = 
8.62, **p < 0.005, n=6). However, bonferroni posttests did not show significant difference 
in cleaved PARP signal in SGZ and SVZ between treatment (+22.3%, p > 0.05 and +18.7%, 
p > 0.05, respectively, n=6). Bonferroni posttests revealed a significant increase in cleaved 
PARP signal in the saline-treated group and the METH-treated one between regions 
(+48.8%, **p < 0.005 and +45.6%, ***p < 0.001, respectively, n=6). ORF-2-positive 
neurons (green) were also positive for cleaved PARP(arrows) , which is a selective marker 
of the late stage of apoptotic cells, The two-way ANOVA did not show significant 
difference in co-localization of ORF-2 and cleaved PARP of treatment (F(1,20) = 0.113, 
p > 0.05, n=6). But it showed a significant increase in region (F(1,20) =  6.04, *p < 0.05, 
n=6). Bonferroni posttests did not reveal significant increase in co-localization between 
ORF-2 and cleaved PARP in neither the saline-treated group nor the METH-treated group 
between regions (+87.6%, p > 0.05, and +78.3%, p > 0.05, respectively, n=6). The data are 
summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, methamphetamine; 
SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ, subventricular 
zone. 
 
 
Figure 3.11. ORF-2 signal co-localizes with the cleaved-PARP signal in some 
immature neuron cells within the neurogenic zones.  Single plain shows that ORF-2 
signal (green) co-localizes with the cleaved-PARP signal (red) in some DCX (white) 
positive cells within the neurogenic zones after binge METH. 
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Figure 3.12. ORF-2 signal co-localizes with the cleaved-PARP signal in some 
proliferating neuronal cells within the neurogenic zones.  Single plain shows that ORF-
2 signal (green) co-localizes with the cleaved-PARP signal (red) in some Ki-67(white) 
positive cells within the neurogenic zones after binge METH.  
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Figure 3.13. Binge METH increases immunoreactivity of GSH.  ORF-2 signal co-
localizes with GSH signal in both SGZ and SVZ.  Representative images from 3 regions 
of the SGZ (A) and the SVZ (B) (as shown in Figure3.2) per condition (saline (a) and 
METH (b)) were taken. The two-way ANOVA showed a significant increase in GSH signal 
(red) of treatment (F(1,20) = 75.6, ***p < 0.001, n=6) and region (F(1,20) = 10.7, **p < 
0.005, n=6). Bonferroni posttests showed a significant increase in GSH signal in SGZ but 
not SVZ between treatment (+28.4%, *p < 0.05 and +46.9%, p > 0.05, respectively, n=6). 
Bonferroni posttests revealed a significant decrease in GSH signal in the saline-treated 
group and the METH-treated group between SGZ and SVZ (-58.9%, ***p < 0.001 and -
52.9%, ***p < 0.001, respectively, n=6). Some ORF-2-positive neurons (green) were also 
positive for GSH (arrows) (red), which is a selective marker of oxidative stress, in both 
saline- and METH-treated rats. The two-way ANOVA showed a significant increase in co-
localization of ORF-2 and GSH of treatment (F(1,20) = 584, ***p < 0.001, n=6), and region 
(F(1,20) =  124, ***p < 0.001, n=6). Bonferroni posttests revealed a significant increase in 
co-localization between ORF-2 and GSH in both SGZ and SVZ between treatment 
(+24.6%, ***p < 0.001, and +57.7%, ***p < 0.001,, respectively, n=6). Bonferroni 
posttests revealed a significant decrease in co-localization between ORF-2 and GSH in 
both the saline-treated group and the METH-treated group between SGZ and SVZ (-55.4%, 
p > 0.05, and -43.8%, p > 0.05, respectively, n=6). The data are summarized in (C). Nuclei 
are depicted in blue. Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open 
reading frame; SGZ, subgranular zone; SVZ, subventricular zone. 
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Chapter 4 DISCUSSION 
4.1. Binge METH Increases ORF-2 Protein Levels in the Neurogenic Zones 
As demonstrated earlier, LINE-1 is a repetitive DNA retrotransposon, which can 
be activated and inserted  into a genome by a copy-and-paste genetic mechanism [95]. It 
encodes two proteins; one protein is ORF-1, an RNA-binding protein, and the other is 
ORF-2, an endonuclease and reverse transcriptase. Both proteins are required for LINE-1 
retrotransposition, and increase of the proteins can serve as a sign of LINE-1 activation. In 
this study, we used the increased level of ORF-2 protein as the sign of LINE-1 activation. 
We observed that binge METH can increase the ORF-2 protein level in the neurogenic 
zones, suggesting the LINE-1 activation. These results confirm our previous findings. Our 
group has reported previously that increased levels of ORF-2 were observed in the SGZ 
and SVZ at 24 hours after the last dose of binge METH [86], suggesting that METH-
triggered LINE-1 activation in the cells residing in the neurogenic zones. Earlier studies 
indicated that LINE-1 is active in very early embryogenesis, and the insertion of LINE-1 
has been detected in neoplastic cells [138, 139]. In normal adult somatic cells, with 
exception of germ cells, LINE-1 is typically quiescent within the genomes of mammals 
[140].  Moreover, there is both evidence for transposition of LINE-1 in neurons [141] and 
evidence for LINE-1 activation in the SGZ [134]. Most importantly, cellular stresses such 
as thermal, oxidative, and genotoxic stress can induce LINE-1 activation [142, 143] 
because neurotoxic doses of binge METH cause hyperthermia as well as oxidative damage 
to proteins, lipids, and DNA [9, 144].  
4.2. Identification of Cell Types Expressing Activated LINE-1 in the 
Neurogenic Zones after Binge METH 
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4.2.1. Intermediate progenitor cells and neuronal cells 
In our previous study [86], after binge METH, ORF-2 increased in both DCX-
positive and DCX-negative cells in the SGZ and SVZ. Doublecortin is a microtubule-
associated protein expressed in type-2b, type-3, and immature granule cells. Therefore, 
previous results indicated LINE-1 activation in neuronal precursors was not only 
differentiating and maturing into neurons but also in other cell types.  
To identify additional cells types in which ORF-2 expression is increased after 
binge METH in the neurogenic zones, we used two neuronal markers (NeuN, MAP2) and 
a marker of proliferating cells (Ki-67) in this study. Firstly, to confirm the previous results, 
we stained the tissue with ORF-2 and DCX. We found that the level of DCX remained the 
same at 24 hours after binge METH. It has been reported that METH (10 nM) can increase 
DCX protein levels, suggesting a potentially enhanced neuronal differentiation. In the same 
study, the results also demonstrated that METH altered DG stem cell properties by delaying 
the cell cycle and decreasing self-renewal capacities [84]. However, another study showed 
that METH had a negative impact on SVZ stem/progenitor cells, inducing cell death and 
inhibiting neurogenesis. Specifically, METH decreased neuronal differentiation and 
maturation at non-toxic concentrations (1-10nM) [135]. In our study, the non-changed level 
of DCX could be explained by the supposition that the suppression of cell proliferation or 
differentiation occurred earlier or later than 24 hours after binge METH. Alternatively, it 
is also possible that initially METH did increase cell differentiation in the SGZ and SVZ 
but later caused the death of differentiating cells which masked the increase. This 
possibility is supported by the results of triple staining for DCX, cleaved PARP, and ORF-
2. Only some DCX and cleaved PARP double-positive cells express ORF-2, suggesting 
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that METH treatment may promote death of DCX-positive cells in the neurogenic zones. 
To explain this discrepancy, an in vitro study in PC12 cells may be necessary to further 
determine the timeline of METH effects in cell proliferation. Our results are in agreement 
with the results of the Muotri group [141]. They found that engineered LINE-1 
retrotransposed in differentiated neuronal precursors derived from rat hippocampus neural 
stem cells. Regarding the effect of binge METH on DCX levels, our finding- that there was 
no difference between the saline and METH rats, agrees with Mandyam’s group’s results, 
who found that intermittent access to METH self-administration had no effect on the 
number of DCX-positive cells in the SGZ [134]. Collectively, these data suggest that 
METH has a different effect on DCX-positive cells in the SGZ, depending on the dose, 
frequency of administration, and stage of cell differentiation. 
Recent studies have disclosed that METH induces a reduction of proliferation in 
both the SVZ and the SGZ [145, 146]. In our study, however, a slight increase of Ki-67 
was observed in the SVZ at 24 hours after binge METH administration. It has been reported 
that acute injection of METH produced a rapid and transient (lasting 7 days) decrease in 
the number of BrdU-positive cells in the rat striatum, but it had no effect on cells in the 
SVZ or DG [147]. Similarly, it was found that acute treatment with METH (25 mg/kg; i.p.) 
suppressed the proliferation of granule cells in the DG of adult gerbils, and this effect was 
transient (the proliferation rate was restored 36 hours after the drug challenge) [148]. Dr. 
Mandyam’s group studied proliferation of progenitors using Ki-67 labeling in rats 
intravenously self-administering METH for an extended access (6 h/day: long access 
(LgA)) or limited access (1 h/day: short access (ShA)). They found that four sessions of 
LgA METH enhanced proliferation while 42 sessions of ShA and LgA METH reduced 
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proliferation [149]. Their group also found that when adult rats were given intermittent 
(occasional) access to METH for 1 hour twice a week, an initial pro-proliferative effect 
was produced, but opposing effects on late progenitors and postmitotic neurons resulted in 
no overall change in neurogenesis [150]. These findings demonstrate the dynamic 
regulation of neurogenesis by METH, and underscore how diverse durations of METH 
access alter distinct aspects of neurogenesis. 
We did not find a significant difference of co-localization of ORF-2 and Ki-67 
between saline and METH treatment using Pearson`s correlation coefficient. However, via 
manually counting the ORF-2 and Ki-67 double positive cells, a significant increase of the 
double positive cells in the neurogenic zone was observed in the METH treated group. 
Banaz`s group transfected porcine aortic endothelial (PAE) with a LINE-1 expression 
vector and generated cell clones harboring retrotransposition events. They demonstrated 
that LINE-1 retrotransposition events lead to the reduction of endothelial cell proliferation 
and migration in a PAE cell mode [151]. Fan’s group structured a siRNA expression vector 
for the LINE-1 ORF-1 encoding sequence and transfected hepatocellular carcinoma cells 
(Bel-7402, SMMC-7721, HepG2) and immortalized hepatocellular cells (LO2). They 
found that the transfection of a LINE-1 ORF-1p siRNA expression vector can efficiently 
reduce the expression of LINE-1 ORF-1 protein detecting by Western blot, and the 
decrease of LINE-1 ORF-1 protein inhibited the proliferation of the above cells on the third 
day (FENG Fan; Regulatory effect of LINE-1 ORF-1p on hepatocellular carcinoma cells 
and proliferation of immortalized hepatocellular cells; Medical Journal of Chinese People's 
Liberation Army 2012-03). However, Li’s group found that overexpression of LINE-1 
ORF-1 protein promoted human colorectal cancer LoVo cell proliferation, and the 
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proliferation of LoVo cells can be inhibited by knocking down the LINE-1 protein using 
siRNA against LINE-1. The in vivo data revealed that LINE-1 ORF-1 protein 
overexpression promoted LoVo tumor growth in nude mice, whereas the siRNA 
knockdown of endogenous LINE-1 ORF-1 protein inhibited tumor growth. These results 
indicated that LINE-1 ORF-1protein could promote LoVo cell proliferation and invasion 
both in vitro and in vivo [152]. Those evident revealed that proliferation accompanies 
LINE-1 activation, which supported our results. However, both double staining and triple 
staining showed that only some ORF-2 positive cells are indeed proliferating cells. 
Regarding mature neurons, we found that binge METH decreases the expression of 
NeuN in the neurogenic zones. Moreover, we did not find a decrease in DCX-positive 
neurons. Therefore, it is possible that some of the mature neurons died as a result of binge 
METH neurotoxicity. Previous studies have shown that METH can not only dysregulate 
neurogenesis but also induce apoptosis, which was followed by death of pyramidal and 
granule neurons [133, 134]. There are studies that have demonstrated that METH treatment 
can induce cell death of calbindin-containing GABA interneurons within the hippocampus 
in animal models [45, 47]. Our result further supports the conclusion that binge METH 
induces apoptosis in the neurogenic zones. Since ORF-2 was not enriched in DCX-positive 
cells, the results suggest that ORF-2 was activated in mature granule neurons by binge 
METH, and that the mature neurons were more susceptible to the effects of neurotoxic 
METH doses than differentiating and immature neurons.  
There is some evidence indicating that LINE-1 is activated in mature cells under 
certain circumstances. For example, LINE-1 retrotransposition has been found in mature 
endothelial cells in addition to endothelial progenitors [151]. Higher LINE-1 DNA 
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methylation levels in the cumulus cells of mature oocytesin Polycystic Ovary Syndrome 
(PCOS) patients than control patients, have been observed. But there was no difference in 
the methylation of cumulus cells in immature oocytes between PCOS and control patients. 
Muotri’s group first discovered that LINE-1 is capable of retrotransposition in these cells 
that also expressed the neuronal marker NeuN [141]. Garcia-Perez’s group further 
demonstrated for the first time that engineered LINE-1 can retrotranspose efficiently in 
mature nondividing neuronal cells. Thus, these findings have proved that the degree of 
somatic mosaicism and the impact of LINE-1 retrotransposition in the human brain may 
be higher than previously thought [153]. However, there is no study testing LINE-1 level 
in mature cells after METH administration. Here, we found that increased amounts of ORF-
2 and NeuN double positive cells were observed in neurogenic zones after METH treatment. 
The possible reasons why we did not see much co-localization between ORF-2 and NeuN 
in SVZ follow. Firstly, there are fewer mature neuron cells in the SVZ compared with the 
SGZ, based on our staining. There are primarily three cell types in the SVZ: type-A, type-
B, and type-C cells. Type-B cells have characteristics of astrocytes and have the potential 
to generate type-C cells, which are the transit-amplifying progenitor cells. The type-C cells 
can further produce type-A cells, which are migrating neuroblasts. Therefore, there is a 
limited number of mature neuron cells in the SVZ. The SVZ has new GABA- and DA-
containing interneurons and these neurons can migrate to the olfactory bulb in most adult 
mammals[154]. METH has been reported to induce apoptosis in these interneurons [155-
157].  According to our data, most NeuN positive cells are located in the portion of the 
striatum adjacent to the SVZ but not within the SVZ. Secondly, there are many types of 
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mature neuronal cells in the brain. It is possible that LINE-1 only retrotransposes in certain 
types of mature neuron cells.  
 Microtubule-associated protein2 is one of the most frequently used markers for 
mature neurons [158, 159], which can stain the whole cell body. Therefore, we used MAP2 
to determine whether LINE-1 affects the cytoskeleton.  However, we did not detect the co-
localization between ORF-2 and MAP2 signals in the cytoskeleton, which indicated that 
METH-related increases in ORF-2 may not be expressed in the cytoskeleton. 
4.2.2. Radial glial-like stem cells and mature glial 
METH has been reported to trigger inflammatory responses in areas where DA and 5-HT 
terminals are damaged. METH affects glial cell (e.g., microglia and astrocytes) activity. 
On the other hand, glial cell activity can modulate the neurotoxic and addictive effects of 
METH [55, 56]. Goncavalez and colleagues found that massive METH doses (30 mg/kg) 
increased GFAP levels in the hippocampi of mice [160]. We found a similar result, that 
binge METH increased expression of GFAP in the neurogenic zones and neighboring CA1-
3 regions, which was likely due to METH’s neurotoxic effects. So far there is no data on 
testing LINE-1 levels in glial cells after METH administration. Our observation that many 
GFAP-positive cells were also positive for ORF-2 suggested that ORF-2 may be mediating 
the inflammatory response in the hippocampi of binge METH-exposed rats.  The 
Muotri group’s results indicated that the glial cells did not support high levels of 
retrotransposition because there was no LINE-1 detected in S100-β-positive [141]. 
However, they discussed that they could not conclude that LINE-10eGFP transgene was 
silencing in glia based on their limited results. Another in vitro experiment based on an 
engineered LINE-1 reporter indicated that glia may support less LINE-1 mobilization than 
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neurons. They transfected human fetal brain stem cells (hCNS-SCns) with an expression 
construct containing a retrotransposition-competent human LINE-1 driven from its native 
promoter, which consisted of a reversed copy of the enhanced green fluorescent protein 
(EGFP) expression cassette. They found EGFP-positive cells can preferentially 
differentiate into glial cells rather than neurons [103]. There is another observation in 
human postmortem tissues that suggests LINE-1 retrotransposition events occur more often 
in neurons than in glia [161, 162]. Upton’s group performed single-cell retrotransposon 
capture sequencing (RC-seq) on individual human hippocampal neurons and glial cells. 
They obtained a mean true positive estimate of 6.5 insertions per glial cell, based on the 
PCR validation rate determined for hippocampal neurons (45.0%). This rate was 52.6% 
lower than the estimated 13.7 insertions for hippocampal neurons. This result means that 
LINE-1 insertions can arise in proliferating neural stem cells prior to glial or neuronal 
commitment, while glial otherwise support less LINE-1 mobilization than neurons. 
However, our result showed that ORF-2 level increased significantly in GFAP-positive 
cells after METH administration, both in mature astrocytes outside the SGZ and SVZ, and 
in gasket cell within the SGZ and SVZ. To explain this, first of all, we must admit that the 
result of an in vitro study may be different than an in vivo study. Secondly, GFAP is a 
specific marker for mature astrocytes, but it is also a marker of the radial-glia-like type-1 
cells which may limit its use in differentiating the cellular population [163]. It is necessary 
to distinguish  radial glia-like cells and mature glial cells. These two types of cells are 
different in structure: radial glia-like cells are more like tadpoles, while glial cells have a 
star-like morphology. As mentioned before, they also have different locations. From our 
data, ORF-2 level increased in both types of cells, which may dilute the real influence 
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between glial cells and LINE-1 activation. To solve this problem, we could use another 
marker of glial cells in a future study. For example, S100β is another specific marker for 
mature astrocytes. We could use S100β to further confirm if LINE-1 increases in astrocytes 
after binge METH. Because METH causes activation of gliosis in the striatum, cortex, and 
hippocampus [55, 56] and we also observed increased ORF-2 immunofluorescence co-
localizing with GFAP immunofluorescence in both the SGZ and SVZ, it is possible that 
METH-induced LINE-1 activation without subsequent retrotransposition may be 
associated with gliosis. 
Enhanced gliogenesis is another reason for the observation of increased GFAP. 
Gliogenesis is the generation of glial cells from progenitors and precursor cells. Dr. 
Mandyam’s group observed that intermittent 1 hour access to METH (I-ShA) and 
voluntary exercise increased gliogenesis in the medial prefrontal cortex [164].  They 
discussed that an I-ShA-induced proliferative environment may be attributable to changes 
in endogenous levels of neurotransmitters in the medial prefrontal cortex, especially DA, 
in which activation of distinct DA receptors have been pro-proliferative [165].  The 
voluntary exercise-induced pro-proliferative environment is possibly attributable to 
changes in vasculature and increased expression of endogenous growth factors that 
promote proliferation [166]. However, this possibility is not likely as exercise is associated 
with neuroprotection. 
4.3. The Role of LINE-1 in the Neurogenic Zones 
LINE-1 is typically quiescent in most somatic cell types. Its retrotransposition 
continues to generate both intra-individual and inter-individual genetic diversity. LINE-1 
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activation is strongly associated with disease development [167]. In developing neurons, 
LINE-1 can express and retrotranspose at a high frequency [168], but its function in mature 
neurons is unknown. 
We used cleaved caspase-3 as a marker of middle-stage apoptosis and cleaved 
PARP as a marker of late apoptosis. We found both signals increased in the brain tissue at 
24 hours after binge METH. METH has already been documented to have a negative 
impact on SVZ stem/progenitor cells, for example inducing cell death and inhibiting 
neurogenesis [135]. Moreover, METH self-administration was reported to cause 
hippocampal apoptosis at a proper dosage [134].  
Our result shows that the ORF-2 signal co-localizes with some, but not all, apoptotic 
markers within the neurogenic zones after METH treatment. This begs the question of 
whether METH-induced increase of LINE-1 is in fact not associated with apoptosis. It is 
too early to make this conclusion. First of all, cleaved caspase-3 and cleaved PARP are 
the markers of caspase-dependent apoptosis. In reality, not only caspases, but also 
calpains [169], cathepsins [170], endonucleases, and other proteases can execute 
programmed cell death. Several models of caspase-independent cell death have been 
described. Moreover, various cell death routes may overlap and different characteristics 
may be displayed at the same time [171]. It is possible that a METH-induced increase of 
LINE-1 is associated with caspase dependent and independent cell death apoptosis. To 
investigate this hypothesis, we could use markers of caspase-independent apoptosis to 
stain brain tissue and quantify the co-localization of the markers and ORF-2. Secondly, 
the time point is another thing to be considered. Cadet’s group found that METH 
treatment in immortalized rat striatal cells (M213) can caused an increase of cleavages of 
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caspase-3 and PARP. They also reported that initial cleavage of caspase-3 and PARP 
were detected at 8 hours post METH exposure. Additionally,  both caspase-3 and PARP 
were almost completely cleaved after 16 and 24 hours post METH exposure [172]. 
Cadet’s group showed the time course of caspase-3 activation in the striatum using 
Western blot analysis (pooled protein samples from 5–6 mice per group were used) [87]. 
They found that caspase-3 was cleaved as early as 8 hours after treatment by 
amphetamine (10 mg/kg, 4 times, every 2 hours). On the other hand, the appearance of 
TUNEL-positive cells was first seen at three days after drug administration. Both in vivo 
and in vitro studies indicate that our METH application model is appropriate to detect 
apoptosis.  
Since we detected the apoptosis at 24 hours after METH injection. It is highly 
possible that the cells within neurogenic zones undergo apoptosis at different points of time. 
There are two potential solutions to fix this problem. One is adding markers for different 
stages of apoptosis. For example, annexin V-FITC is a common marker to specifically 
detect an early-to-medium stage of apoptosis while propidium iodide (PI) can detect the 
late stage of apoptosis. The other potential solution is to conduct some in vitro studies; for 
example, we can artificially induce cellular apoptosis and thereby ensure that all the cells 
undergo apoptosis at the same time. Further to that, we can quantify the co-localization 
between apoptosis markers and ORF-2. However, the co-localization of ORF-2 and 
apoptosis markers is not sufficient to conclude that a METH-induced increase of LINE-1 
is associated with apoptosis. In order to study the function of LINE-1, further studies are 
necessary, for example, we could investigate whether suppressing or over-expressing 
LINE-1 could influence the level of apoptosis. 
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Interestingly, we found that signals of cleaved caspase-3 in the SVZ and SGZ were 
in the nucleus, while most papers presented cytoplasmic staining of cleaved caspase-3. To 
explain this, first of all, we tested our caspase-3 antibody in PC12 cells undergoing stress 
and we were able to obtain the image of clear cytoplasmic staining. Therefore, our antibody 
was deemed reliable and it was shown that METH treatment can increase cleaved caspase-
3 in the nucleus in the SVZ and SGZ. In agreement with our result, there is another paper 
that showed cleaved caspase-3 in the nucleus [103]. In that study, the authors detected cell 
death in the ventricular (VZ)/SVZ of the slice culture which was from a 19-week-old 
human fetus after five days in vitro culture.  It is possible that cleaved caspase-3 migrates 
from the cytoplasm into the nucleus 24 hours after METH exposure. In order to test the 
hypothesis, more in vitro cell studies are required to determine the time course of the 
migration of cleaved caspase-3 from the cytoplasm into the nucleus. Based on the literature, 
caspase-3 is thought to be an essential molecule involved in the nuclear morphological 
changes occurring in apoptotic cells. Moreover, many nuclear substrates for caspase-3 have 
been identified despite the cytoplasmic localization of procaspase-3. Therefore, whether 
cleaved caspase-3 localizes in the nucleus, and how cleaved caspase-3 has access to its 
nuclear targets, are important and unresolved questions. There is a study indicating that the 
translocation of cleaved caspase-3 from the cytoplasm into the nucleus is  associated with  
substrate-like protein(s) during progression of apoptosis [173].  
In addition to the concern of the staining pattern of cleave caspase-3, cleaved PARP 
staining also showed unusual pattern in the SVZ. We observed cleaved PARP staining in 
the cytoplasm instead of the nucleus. The previous study indicated that the  PARP family 
is divided into three separate groups: 1) PARP1, PARPb (short PARP1), PARP2, and 
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PARP3, 2) PARP4 and 3) Tankyrase-1, tankyrase-2a, and its isoform tankyrase-2b (also 
known as PARP5 and PARP6a/b) [174]. PARP1 and 2 are considered to be nuclear 
enzymes and are commonly found in the nuclei of cells. In contrast, tankyrases and PARP3 
are found in both the nucleus and cytoplasm [175]. At the same time, our data also showed 
that most of this cytoplasmic cleaved PARP staining is located at the edge of the SVZ, 
where the epidermal cells are.  
 We further checked whether METH induced increases in OFR-2 is associated with 
oxidative stress. We found that GSH increased at 24 hours after binge METH. Dr. 
Moszczynska examined the influence of binge METH (4×20 mg/kg every 5 hours) and 
chronic daily (20 mg/kg per day for 10 days) administration of METH on the level of total 
glutathione in the brain. The result suggested that binge METH treatment was associated 
with a regionally specific reduction of glutathione in the striatum at three hours after the 
last dose of METH, however, chronic METH administration did not induce a reduction of 
glutathione [66]. It was found that acute administration of METH (5 and 15 mg/kg) resulted 
in production of oxidative stress as demonstrated by decreased glutathione levels in the rat 
striatum and prefrontal cortex[77]. There are other studies that showed that an increased 
GSH level in the brain was observed in METH abusers which was thought to be a protective 
response to counteract the excessive oxidative stress induced by METH [78]. There is also 
a report that demonstrated that  exposure to ionizing radiation, which can cause oxidative 
stress, can induce a rapid but transient decrease of the intracellular level of GSH in the 
brain [79]. Chronic stressors (e.g. restraint, social stress) have been associated with a 
significant reduction of cortical GSH or a reduction of GSH in the whole brain [176, 177]. 
Furthermore, it has been reported that administration of corticosterone (10 mg/kg) 
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significantly decreased the glutathione peroxidase (GSPx) in the hippocampus [178], and 
the levels of the reduced and oxidized forms of GSH in hippocampal cultures [179]. These 
studies further support the association between chronic stress and decreased antioxidants. 
Therefore, the decrease of antioxidant capacity in the brain may be responsible for the 
stress-related oxidative damage. As demonstrated in Chapter 1, METH can cause oxidative 
stress by elevating DA and GLU levels in the striatum and hippocampus [144, 180]. 
Increased ROS can adversely affect DNA, lipids, and cellular proteins, respectively 
resulting in nucleotide oxidation, lipid peroxidation or protein nitration in the striatum and 
hippocampus [144, 181]. The level of GSH, which plays a main role during antioxidant 
defense, will increase under mild oxidative stress but decrease under severe oxidative stress, 
such as METH administration  (4×20 mg/kg) [66]. In the case of our study, we used low 
dosage of METH (4×10 mg/kg) and had a longer recovery time after the last injection (24h 
vs. 3h in the previous study), which may have led to the increased level of GSH. In 
conclusion, both the length of recovery time and dosage of METH affect GSH level. It is 
possible that chronic stress or a high dose administration of METH (4×20 mg/kg every 5 
h) caused a GSH decrease due to its overutilization in the striatum, while binge METH 
(4×10 mg/kg, 24h) induced less oxidative stress, leading to an increased level of GSH in 
the hippocampus.  
            We also found that after METH treatment, ORF-2 co-localized with oxidative stress 
marker GSH in most of cells within the neurogenic zones. This result indicated that METH-
induced increased LINE-1 may be associated with the responses to oxidative stress. This 
conclusion is supported by the previous study which reported the activation of LINE-1 
induced by oxidative stress [182-184]. Wongpaiboonwattana’s group found that the 
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methylation level of LINE-1 significantly decreased in H2O2-treated cells determined via 
PCR. This result indicated that oxidative stress can trigger LINE-1 activation [182]. 
Gross’s group concluded that a decrease of LINE-1 methylation was associated with the 
increased oxidative stress in both healthy and bladder cancer subjects across the various 
tissue types [183]. Giorgi’s group treated neuroblastoma cells with hydrogen peroxide and 
subjected them to an in vitro retrotransposition assay involving an episomal LINE-1(RP). 
Their results indicated that hydrogen peroxide treatment induces an increase of 
retrotransposition of the transiently transfected LINE-1(RP) as well as an increase of the 
endogenous LINE-1 transcripts. Therefore, they concluded that oxidative stress can cause 
LINE-1 dysregulation [184]. Kloypan’s group treated bladder cancer cells (UM-UC-3 and 
TCCSUP) and human kidney cells (HK-2) with 20 μM H2O2 for 72 hours to induce 
oxidative stress. Their finding suggested that the ROS exposure in cells can activate 
glutathione synthesis via the transsulfuration pathway leading to a deficiency of Hcy. The 
lack of Hcy can consequently cause SAM depletion and eventual hypomethylation of 
LINE-1 [185].  As demonstrated in chapter 1, LINE-1 are DNA sequences which can 
change their position within the genome. While undergoing retrotransposition, two open 
reading frames transcribe to RNA and translate to ORF-1 and ORF-2 proteins. These two 
proteins perform LINE-1 retrotransposition [98-101]. In addition to this function, ORF-1 
protein is distinctive in forming large cytoplasmic foci, which are identified as cytoplasmic 
stress granules (LINE-1 ORF1 Protein Localizes in Stress Granules with Other RNA-
Binding Proteins, Including Components of RNA Interference RNA-Induced Silencing 
Complex).  The function of stress granules includes protection of RNA from harmful 
conditions, thus their appearance under stress is a protective response [186]. That could 
 
67 
potentially be the reason why we observe increased co-localization between ORF-2 and 
GSH after METH administration.  
            One topic necessary for future consideration is whether GSH is the appropriate 
marker to test oxidative stress. As demonstrated in Chapter 1, total GSH exists as free form 
or bound to proteinsin cells. The relationship between GSH and ROS is a dynamic balance 
process that underpins reduction/oxidation (redox) regulation and signaling. Since 
glutathione reductase, which can revert free glutathione from its oxidized form (GSSG), is 
constitutively active and inducible upon oxidative stress, free glutathione exists almost 
exclusively in its reduced form. The ratio of reduced to oxidized glutathione within cells is 
often used as a marker of oxidative stress [187-190]. To test the relationship between 
oxidative stress and increased LINE-1 after METH administration, a study to determine 
the ratio of GSH to GSSG is necessary. Moreover, the suppression or overexpression of 
LINE-1 in the cells or animal could serve as models to investigate this relationship. 
In summary, we have determined that OFR-2 increased in mature neurons and 
GFAP-positive cells after METH treatment. To determine whether binge METH induced 
upregulation of ORF-2 in mature neurons and glia, triple staining study for ORF-2, 
GSH:GSSG and GFAP (or NeuN) may be required. 
4.4. Interpretation of the co-localization results 
We used the Pearson correlation coefficient (PCC) to determine the correlation of 
two fluorescence channels and consequently determine the co-localization of signals from 
the two channels [191].  This is a well-established method to determine correlation, and 
has a range of +1 (perfect correlation) to −1 (perfect but negative correlation) with 0 
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denoting the absence of a relationship. Its application to the measurement of co-localization 
between fluorophores is relatively recent [192]. The PCC also has some drawbacks. It is 
not sensitive to differences in signal intensity between the components of an image caused 
by different labeling with fluorochromes, photobleaching, or different settings of 
amplifiers, and the negative values of the correlation coefficient are difficult to interpret 
when the degree of overlap is the quantity to be measured [191]. In our case, OFR-2 showed 
cytoplasmic staining while NeuN, Ki-67, and cleaved PARP staining were located in the 
nucleus. The PCC cannot paint the whole picture because the two stainings in which we 
are interested (e.g. ORF2/NeuN, ORF2/Ki-67) do not actually co-occur. Stereology-based 
counting of cells co-expressing two fluorophores in different cellular compartments is 
warranted. 
4.5. Conclusions and Future Directions 
Our results suggest that systemic administration of neurotoxic doses of binge 
METH increases the activity of LINE-1 in GFAP-positive cells and postmitotic neuronal 
cells as well as in cells with increased GSH in the neurogenic zones. Binge METH can 
induce increased activity of LINE-1 in the neurogenic zones which may not be associated 
with apoptotic cell death but may be associated with responses to oxidative stress.   
As mentioned before, we exclusively evaluated the apoptosis status at 24 hours 
after METH injection. It is highly possible that the cells within neurogenic zones undergo 
apoptosis at different time points, therefore, to better investigate the apoptosis status of 
cells after METH treatment, a in vivo time course is required. In future, to determine the 
relation between LINE1 and METH induced apoptosis, different apoptotic markers (e.g. 
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annexinV-FITC) should be used. In addition, a time course study in PC12 cells after the 
exposure of METH should be conducted to study the relationship between METH-induced 
apoptosis and the activation and nucleus translocation of cleaved caspase-3. Moreover, a 
study to determine the ratio of GSH:GSSG in the zones of interest after binge METH will 
be valuable. Last but not least, studies to investigate the functional link between LINE-1 
and oxidative stress in METH neurotoxicity and to determine LINE-1 function in glial cells 
would be worth performing and would help to explain our results.    
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THE ROLE OF LINE-1 TRANSPOSABLE ELEMENT IN 
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 Methamphetamine (METH) is a widely abused psychostimulant, which 
can cause neurotoxicity in the striatum and hippocampus. Several epigenetic 
changes were identified after binge METH exposure, including histone 
modification, DNA methylation, and changes in miRNA levels. We have 
shown that binge METH increases expression and activity of Long 
INterspersed Element (LINE-1), a transposable element, in doublecortin-
positive neurons within rat neurogenic zones. The goal of the present study 
was to identify which type(s) of cells show increases in LINE-1 following 
binge METH exposure, and determine whether binge METH-induced 
increases in LINE-1 are associated with cell death. To achieve this goal, male 
adult Sprague Dawley rats were treated with binge METH (4x 10mg/kg, i.p. 
 
93 
every 2 h) or saline, sacrificed 24 hours later, and examined for LINE-1 
expression and either markers of cell types in neurogenic zones or signs of 
apoptosis within the neurogenic zones. We found that increased LINE-1 
expression co-localized with most GFAP-positive cells in both the 
subgranular zone (SGZ) and subventricular zone (SVZ), as well as most 
NeuN-positive cells in SGZ. We also found that LINE-1 expression co-
localized with some, but not all, apoptotic marker expression within the 
neurogenic zones. However, LINE-1 expression did co-localize with an 
oxidative stress marker. Collectively, our data suggest that systemic 
administration of neurotoxic doses of binge METH increases the activity of 
LINE-1 mostly in glial cells and post-mitotic cells, and may be associated 
with responses to oxidative stress and/or gliosis. Supported by NIH/NIDA 
R01 DA034783   
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